Haben Sie sich noch nicht registriert? Hier kostenlos Ihr Konto eröffnen.
Passwort vergessen? Wir werden Ihnen einen Zurücksetzen Link senden
17 Januar 2024
MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials.
4 Juli 2023
MegaPro Biomedical MPB-1523 Clinical Phase II Trial Results Published in International Journals
15 November 2022
MegaPro Biomedical MPB-1734 Receives Composition Patent for New Dosage Form of Anticancer Drug which enhanced the immune-combination therapy
26 Juli 2022
MegaPro Successfully Completes the biological evaluations of IOP as Vaccine Adjuvant T cell mediated Immunity is Substantially Enhanced, Improving the Efficacy of Vaccines
14 Juli 2022
MegaPro, CCPC, and Wellbridge Jointly Establishes an Inhalation Dosage Form Company
25 November 2020
New dosage form (or formulation) of anticancer drug MPB-1734 passes the US FDA clinical I/IIa IND application
13 Dezember 2019
Development of biomedical technology has led to unprecedented collaboration for a new start-up: Strategic Cooperation between MegaPro and China Chemical & Pharmaceutical Co.
14 September 2018
MegaPro Biomedical Co. is invited to attend 2018 China BioMed Innovation and Investment Conference (CBIIC) and roadshow present